First of all, Mr. Glover, thank you for being here today. I'm glad to hear that Health Canada is making it clear that you do support public reporting and that it be a requirement, as you noted in your brief today.
The huge issue that we're missing is the lack of any oversight. We hear a lot of information about different roles and who does what, whether it's provinces or the purchasers, but there has been a lack of oversight and leadership.
We had some suggestions today. It's unfortunate that you didn't hear the earlier presentations, but the one in particular that my colleague referred to was a suggestion that Health Canada should convene an expert committee to look at the off-patent drugs that are considered critical and are supplied by only one or two companies. Never mind if they are short or not; it would be just to have an inventory of the drugs that are very well used and are supplied by only one or two suppliers. Following that, possible alternative sources could be identified through Health Canada with this expert committee, so that other arrangements could be made if there were an emergency. That, to me, is very much based on public interest and public health interest, which is part of your mandate as well as that of PHAC.
I wonder if you could respond to that.
As well, we know that the Auditor General has said that Health Canada has been slow to approve alternate suppliers. This has also been part of the problem. I know that right now we're under an expedited process, but how long will that continue? I think the Auditor General did make that a very clear issue in terms of the approval process itself.